Pablo Gafas, Alicia de
Recommendations on the use of everolimus in lung transplantation. [artículo] - Transplantation Reviews, 2013 - 27(1):9-16.
Formato Vancouver:
De Pablo A, Santos F, Solé A, Borro JM, Cifrian JM, Laporta R et al. Recommendations on the use of everolimus in lung transplantation. Transplant Rev (Orlando). 2013 Jan;27(1):9-16.
PMID: 23276646
Contiene 89 referencias
The antiproliferative effect of everolimus provides a therapeutic option in the immunosuppression therapy of lung transplantation, by reducing both the risk of acute rejection and the process of progressive fibrosis that determines chronic graft rejection. However, few data on the use of everolimus in lung transplantation have been published to date, and the specific indications of the drug, along with the most adequate time for its introduction or dosing, have not been defined yet. The aim of this article is to propose recommendations for the use of everolimus in lung transplant recipients, including indications, dosing schedules and the use of concomitant immunosuppression. This consensus document has been developed by experts of all the Spanish lung transplant groups from the review of the existing literature and the clinical experience.
Recommendations on the use of everolimus in lung transplantation. [artículo] - Transplantation Reviews, 2013 - 27(1):9-16.
Formato Vancouver:
De Pablo A, Santos F, Solé A, Borro JM, Cifrian JM, Laporta R et al. Recommendations on the use of everolimus in lung transplantation. Transplant Rev (Orlando). 2013 Jan;27(1):9-16.
PMID: 23276646
Contiene 89 referencias
The antiproliferative effect of everolimus provides a therapeutic option in the immunosuppression therapy of lung transplantation, by reducing both the risk of acute rejection and the process of progressive fibrosis that determines chronic graft rejection. However, few data on the use of everolimus in lung transplantation have been published to date, and the specific indications of the drug, along with the most adequate time for its introduction or dosing, have not been defined yet. The aim of this article is to propose recommendations for the use of everolimus in lung transplant recipients, including indications, dosing schedules and the use of concomitant immunosuppression. This consensus document has been developed by experts of all the Spanish lung transplant groups from the review of the existing literature and the clinical experience.
